Argos Therapeutics, Inc.

Argos Therapeutics, Inc.

Argos Therapeutics, Inc.

Date Founded



4233 Technology Drive, Durham, NC, 27704, USA

Type of Company


Employees (Worldwide)

101 - 250


Pension Funds & Sovereign Wealth
Hospitals & Patient Services
Medical Support Services

Company Description

Argos Therapeutics, Inc. is a biopharmaceutical company. It engages in development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its proprietary technology platform called Arcelis. The firm's product include AGS-003 for the treatment of metastatic renal cell carcinoma, and other cancers; and AGS-004 for the treatment of human immunodeficiency virus. The company was founded by Bruce A. Sullenger, Eli Gilboa, John A. Irick and Ralph M. Steinman on May 8, 1997 and is headquartered in Durham, NC.

Contact Data
Trying to get in touch with decision makers at Argos Therapeutics, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Operating Officer

Chief Restructuring Officer

Director Quality Assurance



Senior Manager


Production Manager

Project Manager

Board of Directors

Adjunct Professor of Business Management & Marketing at The University of North Carolina at Wilmington

Chief Executive Officer at Veset International Ltd.

Paths to Argos Therapeutics, Inc.
Potential Connections via
Relationship Science
Argos Therapeutics, Inc.
Recent Transactions
Details Hidden

Argos Therapeutics, Inc. issued USD Common Stock

Details Hidden

Argos Therapeutics, Inc. issued USD Common Stock

Details Hidden

Argos Therapeutics, Inc. raised money in a private placement transaction

Transaction Advisors

Advised onArgos Therapeutics, Inc. issued USD Common Stock


Advised onArgos Therapeutics, Inc. issued USD Common Stock


Advised onArgos Therapeutics, Inc. issued USD Common Stock


Advised onArgos Therapeutics, Inc. issued USD Common Stock

Chief Compliance Officer

Advised onArgos Therapeutics, Inc. issued USD Common Stock

Legal Advisor

Advised onArgos Therapeutics, Inc. issued USD Common Stock

Advisors & Consultants
Pension Consultant

The Vanguard Group is an American investment management company based in Malvern, Pennsylvania, that manages approximately $3.4 trillion[1] in assets. It is the largest provider of mutual funds and now the second-largest provider of exchange-traded funds (ETFs) in the world after BlackRock, with about $451 billion in ETF assets under management, as of March 2015.[3] It offers mutual funds and other financial products and services to retail and institutional investors in the United States and abroad. Founder and former chairman John C. Bogle is credited with the creation of the first index fund available to individual investors,[4] the popularization of index funds generally,[5] and driving costs down across the mutual fund industry.

Pension Consultant

Altegris Advisors seeks to minimize investor risk while maximizing potential returns. The firm follows a disciplined process for identifying, evaluating, selecting, and monitoring investment talent across a spectrum of alternative strategies, including managed futures, global macro, long/short equity, event-driven, and others. The Investment Committee generally (i) performs an ongoing top-down strategy review to determine any potential opportunities for the lineup of strategies recommended by, or allocated to, by the firm and (ii) directs the Altegris Advisors’ research team as to a bottom-up approach to identify potential managers or strategies that may meet their performance objectives and investment strategy themes.

Pension Consultant

HCM uses fundamental security analysis methods. They perform fundamental analysis on a securities value by looking at economic factors, such as interest rates and the overall state of the economy, information about companies, revenues, earnings, future growth, return on equity, profit margins and other data to determine underlying value and potential for future growth. Their security analysis information is based on a number of sources including financial newspapers, periodicals, commercially available investment services, company prepared information, general market and financial information, due diligence reviews, and specific investment analysis that our clients may request.


Chief Executive Officer at CoImmune, Inc.


Chief Financial & Accounting Officer at Allena Pharmaceuticals, Inc.


Professional at Berry & Company Public Relations


The University of North Carolina at Chapel Hill also known as UNC, UNC-Chapel Hill, Chapel Hill, North Carolina, or simply Carolina is a coeducational public research university located in Chapel Hill, North Carolina, United States. North Carolina has been consistently ranked among the highest ranked universities in the United States and is one of the original eight Public Ivy schools that provide an Ivy League experience for a public schooling price. After being chartered in 1789, the university first began enrolling students in 1795, which allows it to be one of three schools to claim the title of the oldest public university in the United States.

Green Cross Corp. engages in the manufacture and sale of pharmaceutical products. Its products include medicines for blood, over the counter drugs, generals, vaccines, and others. The company was founded on November 1, 1969 and is headquartered in Yongin, South Korea.

Chongqing Lummy Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of pharmaceutical. Its products include tumor drugs, antibacterial drugs, antifungal drugs, antiviral agent, digestive system agents, immune system agents, blood system agents, cardiovascular system agents, nervous system agents, electrolyte and acid-base balance and nutritional, liver disease auxiliary drugs, endocrinology system drugs, Chinese patent drugs, base large infusion, American ginseng and active pharmaceutical ingredients. The company was founded on September 6, 1999 and is headquartered in Chongqing, China.

Key Stats and Financials As of
Market Capitalization
Total Enterprise Value
Earnings Per Share
Details Hidden

DC Bio Corp. develops technology for application to cancer and diseases associated with chronic viral infections. The company is headquartered in Halifax, Canada.

Details Hidden

Forbion is an active manager which invests in life sciences and biomedical technology companies in Northwest Europe and the US. The firm focuses on companies that have innovative technologies and drug development programs. In Europe, Forbion tends to take the lead investor role, while in the US they prefer to be a co-lead investor, making initial investments ranging from EUR 1 - EUR 7 million, and participates in follow-on investments. Forbion generally takes a seat on the board of directors.

Details Hidden

Intersouth Partners focuses on seed and early-stage investments in the information technology and life sciences sectors. They invest across the Southeastern US, primarily in the corridor from Baltimore through Florida, including Washington, DC, the Research Triangle region and Atlanta.

Details Hidden

Aurora Funds invests in companies located in the US. The firm targets companies operating in the fields of healthcare and information technology. The firm provides financing for early stage capital requirements.

Compagnie de Saint-Gobain SA Industrial Machinery & Manufacturing | Courbevoie, Fra

Compagnie de Saint-Gobain SA engages in designing, manufacturing, and distribution of materials and solutions for the construction, mobility, healthcare and other industrial application markets. The firm operates through the following segments: High Performance Solutions (HPS), Northern Europe, Southern Europe, Americas, and Asia-Pacific. Its brands include CertainTeed, Gyproc, ISOVER, Weber, Placo, British Gypsum, Rigips, bassetts, brasilit, and cebrace. The company was founded in 1665 and is headquartered in Courbevoie, France.

Invetech Pty Ltd. Other Manufacturing | Melbourne, Australia

Invetech Pty Ltd. operates as an engineering consultancy firn. It specializes in product design, instrument development, and contract manufacturing in the healthcare markets. The firm's capabilities include fluidics, optics, motion, thermal control, consumable, industrial, experience and cartridge design, connectivity and systems integration, and quality systems. The company is headquartered in Melbourne, Australia.

Merck & Co., Inc. Pharmaceuticals - Kenilworth, NJ

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Amgen, Inc. Biotechnology - Thousand Oaks, CA

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Exelixis, Inc. Biotechnology - South San Francisco, CA

Exelixis is a biopharmaceutical company committed to developing and commercializing small molecule therapies for the treatment of cancer. In advancing our first product, COMETRIQ, from discovery to market, we have established an effective and integrated infrastructure that encompasses the entire biopharmaceutical development continuum. We are committed to excellence in all aspects of our work and are dedicated to improving the care and outcome of cancer patients.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Argos Therapeutics, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Argos Therapeutics, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Argos Therapeutics, Inc..